Evidence map›Paper›PMID 35200620›Full record

ReviewMarine drugs2022

Anti-Larval and Anti-Algal Natural Products from Marine Microorganisms as Sources of Anti-Biofilm Agents.

Kai-Ling Wang, Zheng-Rong Dou, Gao-Fen Gong, Hai-Feng Li, Bei Jiang, Ying Xu

Open access · goldAbstract readReview
In one paragraph

Review in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Enhanced antifouling properties of marine antimicrobial peptides by PEGylation.Frontiers in bioengineering and biotechnology · 2023
    Article
  11. Article
  12. DNase inhibits early biofilm formation inFrontiers in cellular and infection microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kai-Ling WangYunnan Key Laboratory of Screening and Research on Anti-Pathogenic Plant Resources from West Yunnan (Cultivation), Institute of Materia Medica, College of Pharmacy, Dali University, Dali 671000, China.
Zheng-Rong DouYunnan Key Laboratory of Screening and Research on Anti-Pathogenic Plant Resources from West Yunnan (Cultivation), Institute of Materia Medica, College of Pharmacy, Dali University, Dali 671000, China.
Gao-Fen GongYunnan Key Laboratory of Screening and Research on Anti-Pathogenic Plant Resources from West Yunnan (Cultivation), Institute of Materia Medica, College of Pharmacy, Dali University, Dali 671000, China.
Hai-Feng LiYunnan Key Laboratory of Screening and Research on Anti-Pathogenic Plant Resources from West Yunnan (Cultivation), Institute of Materia Medica, College of Pharmacy, Dali University, Dali 671000, China.
Bei JiangYunnan Key Laboratory of Screening and Research on Anti-Pathogenic Plant Resources from West Yunnan (Cultivation), Institute of Materia Medica, College of Pharmacy, Dali University, Dali 671000, China.
Ying XuShenzhen Key Laboratory of Marine Bioresource & Eco-Environmental Science, Shenzhen Engineering Laboratory for Marine Algal Biotechnology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China.
Dali University · CNShenzhen University · CN

Funding

the Development and Utilization of Characteristic Medicinal Plants in Western Yunnan & Bai Nationality Medicines ZKLX2019106the National Natural Science Foundations of China 32060032the National Natural Science Foundations of China 41706155the Natural Science Foundation of Yunnan Province of China 202001AT070022the Shenzhen Science and Technology Program JCYJ20210324093409025
6 · The paper itself

Abstract

Bacteria growing inside biofilms are more resistant to hostile environments, conventional antibiotics, and mechanical stresses than their planktonic counterparts. It is estimated that more than 80% of microbial infections in human patients are biofilm-based, and biofouling induced by the biofilms of some bacteria causes serious ecological and economic problems throughout the world. Therefore, exploring highly effective anti-biofilm compounds has become an urgent demand for the medical and marine industries. Marine microorganisms, a well-documented and prolific source of natural products, provide an array of structurally distinct secondary metabolites with diverse biological activities. However, up to date, only a handful of anti-biofilm natural products derived from marine microorganisms have been reported. Meanwhile, it is worth noting that some promising antifouling (AF) compounds from marine microbes, particularly those that inhibit settlement of fouling invertebrate larvae and algal spores, can be considered as potential anti-biofilm agents owing to the well-known knowledge of the correlations between biofilm formation and the biofouling process of fouling organisms. In this review, a total of 112 anti-biofilm, anti-larval, and anti-algal natural products from marine microbes and 26 of their synthetic analogues are highlighted from 2000 to 2021. These compounds are introduced based on their microbial origins, and then categorized into the following different structural groups: fatty acids, butenolides, terpenoids, steroids, phenols, phenyl ethers, polyketides, alkaloids, flavonoids, amines, nucleosides, and peptides. The preliminary structure-activity relationships (SAR) of some important compounds are also briefly discussed. Finally, current challenges and future research perspectives are proposed based on opinions from many previous reviews.

Indexed as

AnimalsAnti-Bacterial AgentsAquatic OrganismsBacteriaBiofilmsBiofoulingBiological ProductsHumansLarvaStructure-Activity RelationshipAnti-Bacterial AgentsBiological Productsanti-algalanti-biofilmantifoulinganti-larvalbiofoulingmarine microorganismsnatural products

Identifiers

PMID35200620
PMCPMC8876061
OpenAlexW4207061703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.